{"id":"l-t4-t3-thyroid-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Heat intolerance"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL2108878","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levothyroxine (L-T4) is converted peripherally to the active form T3 and acts as a pro-hormone, while liothyronine (T3) is the active thyroid hormone that directly binds thyroid hormone receptors in target tissues. Together, they restore euthyroid state by activating nuclear thyroid hormone receptors, which regulate metabolism, energy production, and cardiovascular function. This combination approach aims to more closely mimic natural thyroid hormone physiology compared to T4 monotherapy.","oneSentence":"L-T4+T3 combination therapy replaces deficient thyroid hormones by providing both levothyroxine (T4) and liothyronine (T3) to restore normal thyroid hormone levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:18.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypothyroidism"},{"name":"Thyroid hormone replacement after thyroidectomy or radioactive iodine therapy"}]},"trialDetails":[{"nctId":"NCT07424183","phase":"PHASE2","title":"T4/T3 Therapy in Hypothyroidism","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-03","conditions":"Hypothyroidism Primary","enrollment":60},{"nctId":"NCT06647602","phase":"","title":"Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-09-01","conditions":"Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine","enrollment":40},{"nctId":"NCT06660823","phase":"PHASE3","title":"Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-30","conditions":"Cardiac Surgery Intensive Care Treatment, Delayed Recovery From Anaesthesia, Euthyroid Sick Syndrome","enrollment":70},{"nctId":"NCT05682482","phase":"PHASE3","title":"LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.","status":"RECRUITING","sponsor":"M. Medici","startDate":"2022-10-07","conditions":"Autoimmune Hypothyroidism","enrollment":600},{"nctId":"NCT04111536","phase":"PHASE1, PHASE2","title":"Developing Oral LT3 Therapy for Heart Failure - HFpEF","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-03-08","conditions":"Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome","enrollment":28},{"nctId":"NCT04112316","phase":"PHASE1, PHASE2","title":"Developing Oral LT3 Therapy for Heart Failure - HFrEF","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-02-11","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome","enrollment":28},{"nctId":"NCT04782856","phase":"PHASE2","title":"Energy Metabolism in Thyroidectomized Patients","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2020-10-28","conditions":"Thyroid Goiter, Hypothyroidism, Thyroid Cancer","enrollment":13},{"nctId":"NCT06353555","phase":"NA","title":"Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-10-11","conditions":"Intracerebral Hemorrhage, Low T3 Syndrome, Neurocritical Care","enrollment":100},{"nctId":"NCT05461820","phase":"PHASE4","title":"Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-05-01","conditions":"Graves Disease, Relapse, Treatment","enrollment":240},{"nctId":"NCT03787303","phase":"PHASE2","title":"Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma","status":"TERMINATED","sponsor":"Aultman Health Foundation","startDate":"2019-03-01","conditions":"Metastatic Breast Cancer, Thyroid Dysfunction","enrollment":7},{"nctId":"NCT05247476","phase":"PHASE4","title":"Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.","status":"UNKNOWN","sponsor":"Zhongshan Hospital Xiamen University","startDate":"2021-10-18","conditions":"Thyroid Cancer, Papillary, Hypothyroidism","enrollment":50},{"nctId":"NCT03173742","phase":"PHASE1","title":"Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)","status":"COMPLETED","sponsor":"Insud Pharma","startDate":"2016-03","conditions":"Helminthiasis","enrollment":54},{"nctId":"NCT02395913","phase":"PHASE1","title":"Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)","status":"COMPLETED","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2013-07","conditions":"Healthy Male","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"L-T4+T3 (thyroid tablet)","genericName":"L-T4+T3 (thyroid tablet)","companyName":"Zhongshan Hospital Xiamen University","companyId":"zhongshan-hospital-xiamen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-T4+T3 is a thyroid tablet that has been studied in various clinical trials for conditions such as hypothyroidism, thyroid cancer, and heart failure with reduced ejection fraction. The tablet is not a performance-enhancing substance, as it is not listed among the interventions in the clinical trials on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}